Anti-cytokine therapies in T1D: Concepts and strategies

Ablamunits, 2012, Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation, Diabetes, 61, 145, 10.2337/db11-1033 Arif, 2011, Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death, Diabetes, 60, 2112, 10.2337/db10-1643 Bending, 2009, Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice, J. Clin. Invest., 119, 565, 10.1172/JCI37865 Benson, 2011, Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders, MAbs, 3, 535, 10.4161/mabs.3.6.17815 Bettelli, 2006, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, 441, 235, 10.1038/nature04753 Bradshaw, 2009, Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells, J. Immunol., 183, 4432, 10.4049/jimmunol.0900576 Cavelti-Weder, 2012, Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes, Diabetes Care, 35, 1654, 10.2337/dc11-2219 Croxtall, 2011, Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis, Drugs, 71, 1733, 10.2165/11207530-000000000-00000 Dinarello, 2005, The many worlds of reducing interleukin-1, Arthritis Rheum., 52, 1960, 10.1002/art.21107 Dinarello, 2009, Immunological and inflammatory functions of the interleukin-1 family, Annu. Rev. Immunol., 27, 519, 10.1146/annurev.immunol.021908.132612 Dinarello, 2011, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood, 117, 3720, 10.1182/blood-2010-07-273417 Ehses, 2009, IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat, Proc. Natl. Acad. Sci. U. S. A., 106, 13998, 10.1073/pnas.0810087106 Ellingsgaard, 2011, Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells, Nat. Med., 17, 1481, 10.1038/nm.2513 Elliott, 2009, Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases, Ann. N. Y. Acad. Sci., 1182, 97, 10.1111/j.1749-6632.2009.05070.x Emamaullee, 2009, Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice, Diabetes, 58, 1302, 10.2337/db08-1113 Ferraro, 2011, Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes, Diabetes, 60, 2903, 10.2337/db11-0090 Fujihira, 2000, Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice, Diabetes, 49, 1998, 10.2337/diabetes.49.12.1998 Herold, 2005, A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of type 1 diabetes, Diabetes, 54, 1763, 10.2337/diabetes.54.6.1763 Hingorani, 2012, The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis, Lancet, 379, 1214, 10.1016/S0140-6736(12)60110-X Honkanen, 2010, IL-17 immunity in human type 1 diabetes, J. Immunol., 185, 1959, 10.4049/jimmunol.1000788 Joseph, 2012, IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes, J. Immunol., 188, 216, 10.4049/jimmunol.1101215 Keymeulen, 2010, Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass, Diabetologia, 53, 614, 10.1007/s00125-009-1644-9 Korn, 2008, IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells, Proc. Natl. Acad. Sci. U. S. A., 105, 18460, 10.1073/pnas.0809850105 Lal, 2009, Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation, J. Immunol., 182, 259, 10.4049/jimmunol.182.1.259 Larsen, 2007, Interleukin-1-receptor antagonist in type 2 diabetes mellitus, N. Engl. J. Med., 356, 1517, 10.1056/NEJMoa065213 Leonardi, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), Lancet, 371, 1665, 10.1016/S0140-6736(08)60725-4 Mandrup-Poulsen, 1996, The role of interleukin-1 in the pathogenesis of IDDM, Diabetologia, 39, 1005, 10.1007/BF00400649 Mandrup-Poulsen, 1987, Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity, J. Immunol., 139, 4077, 10.4049/jimmunol.139.12.4077 Mandrup-Poulsen, 2010, Blockade of interleukin 1 in type 1 diabetes mellitus, Nat. Rev. Endocrinol., 6, 158, 10.1038/nrendo.2009.271 Martinon, 2009, The inflammasomes: guardians of the body, Annu. Rev. Immunol., 27, 229, 10.1146/annurev.immunol.021908.132715 Marwaha, 2010, Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes, J. Immunol., 185, 3814, 10.4049/jimmunol.1001860 Mastrandrea, 2009, Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study, Diabetes Care, 32, 1244, 10.2337/dc09-0054 Murakami, 2011, The value of blocking IL-6 outside of rheumatoid arthritis: current perspective, Curr. Opin. Rheumatol., 23, 273, 10.1097/BOR.0b013e3283456797 Nicoletti, 1999, Endogenous interleukin-12 only plays a key pathogenetic role in non-obese diabetic mouse diabetes during the very early stages of the disease, Immunology, 97, 367, 10.1046/j.1365-2567.1999.00836.x Orban, 2011, Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial, Lancet, 378, 412, 10.1016/S0140-6736(11)60886-6 Oslowski, 2012, Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome, Cell Metab., 16, 265, 10.1016/j.cmet.2012.07.005 Papp, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet, 371, 1675, 10.1016/S0140-6736(08)60726-6 Pescovitz, 2009, Rituximab, B-lymphocyte depletion, and preservation of beta-cell function, N. Engl. J. Med., 361, 2143, 10.1056/NEJMoa0904452 Rose-John, 2007, The IL-6/sIL-6R complex as a novel target for therapeutic approaches, Expert Opin. Ther. Targets, 11, 613, 10.1517/14728222.11.5.613 Rothe, 1997, Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2, Diabetologia, 40, 641, 10.1007/s001250050728 Sakata, 2008, Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules, Diabetes Res. Clin. Pract., 80, 352, 10.1016/j.diabres.2008.01.030 Samson, 2012, Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis, Arthritis Rheum., 64, 2499, 10.1002/art.34477 Sandborn, 2012, Ustekinumab induction and maintenance therapy in refractory Crohn's disease, N. Engl. J. Med., 367, 1519, 10.1056/NEJMoa1203572 Schneider, 2008, The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells, J. Immunol., 181, 7350, 10.4049/jimmunol.181.10.7350 Schultz, 2010, Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases, PLoS One, 5, e14328, 10.1371/journal.pone.0014328 Suarez-Farinas, 2012, Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis, J. Invest. Dermatol., 132, 2552, 10.1038/jid.2012.184 Sumpter, 2011, Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes, Pediatr. Diabetes, 12, 656, 10.1111/j.1399-5448.2011.00761.x Sun, 2007, A new class of reverse signaling costimulators belongs to the TNF family, J. Immunol., 179, 4307, 10.4049/jimmunol.179.7.4307 Sutherland, 2009, Interleukin-21 is required for the development of type 1 diabetes in NOD mice, Diabetes, 58, 1144, 10.2337/db08-0882 Tanaka, 2012, Therapeutic targeting of the interleukin-6 receptor, Annu. Rev. Pharmacol. Toxicol., 52, 199, 10.1146/annurev-pharmtox-010611-134715 Trembleau, 1995, Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice, J. Exp. Med., 181, 817, 10.1084/jem.181.2.817 Trembleau, 1997, Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes, Eur. J. Immunol., 27, 2330, 10.1002/eji.1830270930 Trembleau, 2003, IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma, J. Immunol., 170, 5491, 10.4049/jimmunol.170.11.5491 Vendrame, 2010, Recurrence of type 1 diabetes after simultaneous pancreas–kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells, Diabetes, 59, 947, 10.2337/db09-0498 Yasuda, 1998, Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice, J. Clin. Invest., 102, 1807, 10.1172/JCI2675 Zaghi, 2012, Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis, J. Drugs Dermatol., 11, 160 Zhang, 2012, IFN-gamma induced by IL-12 administration prevents diabetes by inhibiting pathogenic IL-17 production in NOD mice, J. Autoimmun., 38, 20, 10.1016/j.jaut.2011.11.017 Zhou, 2010, Thioredoxin-interacting protein links oxidative stress to inflammasome activation, Nat. Immunol., 11, 136, 10.1038/ni.1831 Zhou, 2009, Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo, Nat. Immunol., 10, 1000, 10.1038/ni.1774 Schneider, 2013, In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive Tregs involves IL-6-mediated signaling, Sci. Transl. Med., 5, 10.1126/scitranslmed.3004970